Selected Important Safety Information
Patients with neutropenia: The safety and efficacy of SIVEXTRO® (tedizolid phosphate) in patients with neutropenia
(neutrophil counts <1000 cells/mm3) have not been adequately evaluated. In an animal model of
infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes.
Alternative therapies should be considered when treating patients with neutropenia.
Clostridium difficile–associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has
been reported with nearly all systemic antibacterial agents, including SIVEXTRO. Evaluate all
patients who present with diarrhea following antibiotic use. Careful medical history is necessary
because CDAD has been reported to occur more than two months after the administration of
antibacterial agents. If CDAD is suspected or confirmed, antibacterial use not directed against C.
difficile should be discontinued, if possible.
Development of drug-resistant bacteria: Prescribing SIVEXTRO in the absence of a proven or
strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the
patient and increases the risk of the development of drug-resistant bacteria.
Adverse Reactions: The most common adverse reactions for SIVEXTRO are nausea (8%), headache
(6%), diarrhea (4%), vomiting (3%), and dizziness (2%).